Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer

Table 7 The predictive value of lactate dehydrogenase in microsatellite stable metastatic colorectal cancer patients receiving chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy

Time	AUC	95%CI	Cut-off	Sensitivity	Specificity
9 months	0.81	0.63-0.98	154	0.89	0.75
12 months	0.71	0.47-0.95	343	0.84	0.73
15 months	0.79	0.54-1.04	232	0.93	0.71

AUC: Area under the curve; CI: Confidence interval.